- Current report filing (8-K)
June 06 2011 - 3:45PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): June 3, 2011
SUNESIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-51531
|
|
94-3295878
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
395 Oyster Point Boulevard, Suite 400
South San Francisco, California
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650) 266-3500
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.07. Submission of Matters to a Vote of Security Holders.
The 2011 Annual Meeting of Stockholders (the Annual Meeting) of Sunesis Pharmaceuticals, Inc. was held on June 3, 2011. Proxies for the
Annual Meeting were solicited by our Board of Directors (the Board) pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition to the Boards solicitation. There
were 46,027,474 shares of common stock entitled to vote at the Annual Meeting. A total of 37,499,610 shares were represented at the Annual Meeting in person or by proxy. The final votes on the proposals presented at the meeting were as follows:
Proposal No. 1
Matthew K. Fust, David C. Stump, M.D. and Daniel N. Swisher, Jr. were elected as directors to hold office until the 2014 Annual Meeting of
Stockholders by the following vote:
|
|
|
|
|
|
|
Nominee
|
|
For
|
|
Withheld
|
|
Broker Non-Votes
|
Matthew K. Fust
|
|
22,105,858
|
|
3,169,089
|
|
12,224,663
|
David C. Stump, M.D.
|
|
22,248,634
|
|
3,026,313
|
|
12,224,663
|
Daniel N. Swisher, Jr.
|
|
25,115,471
|
|
159,476
|
|
12,224,663
|
In addition to the directors
elected above, Edward Hurwitz, Helen S. Kim and Dayton Misfeldt will continue to serve as directors until the 2012 Annual Meeting of Stockholders and until their successors are elected and have qualified, or until their earlier death, resignation or
removal. James W. Young, Ph.D. and Homer L. Pearce, Ph.D. will continue to serve as directors until the 2013 Annual Meeting of Stockholders and until their successors are elected and have qualified, or until their earlier death, resignation or
removal.
Proposal No. 2
The selection by the Audit Committee of the Board of Ernst & Young LLP as our independent registered public accounting firm for the year ending
December 31, 2011 was ratified by the following vote:
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
37,141,308
|
|
85,605
|
|
272,697
|
Proposal No. 3
Our 2011 Equity Incentive Plan was approved by the following vote:
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
24,252,501
|
|
951,789
|
|
70,657
|
|
12,224,663
|
Proposal No. 4
Our 2011 Employee Stock Purchase Plan was approved by the following vote:
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
24,406,687
|
|
802,523
|
|
65,737
|
|
12,224,663
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SUNESIS PHARMACEUTICALS, INC.
|
Dated: June 6, 2011
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Daniel N. Swisher, Jr.
|
|
|
|
|
|
|
Daniel N. Swisher, Jr.
|
|
|
|
|
|
|
President and Chief Executive Officer
|
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Aug 2023 to Aug 2024